1.68
1.68 (-0.61%)
As of Feb 16, 2022
Kaleido Biosciences, Inc. [KLDO]
Source:
Company Overview
We have initiated a process to explore a range of strategic alternatives to maximize shareholder value and have engaged professional advisors, including an investment banker to act as a strategic advisor for this process. Potential strategic alternatives that may be evaluated include a sale or merger of the Company or securing additional financing or partnerships that would enable further development of our programs. There can be no assurance that this strategic review process will result in our pursuing any transaction or that any transaction, if pursued, will be completed. We aim to run this strategic review process into mid-April 2022. Additionally, there can be no assurances that any particular course of action, business arrangement or transaction, or series of transactions, will be pursued, successfully consummated or lead to increased stockholder value. If the strategic process is unsuccessful, our Board may decide to pursue a dissolution and liquidation. In the event of such liquidation or other wind-down event, holders of our securities will likely suffer a total loss of their investment.
| Country | United States |
| Headquarters | bedford, massachusetts |
| Phone Number | 617-674-9000 |
| Industry | manufacturing |
| CEO | Daniel L. Menichella |
| Website | kaleido.com |
Financial Overview (Dollars in Millions)
| Revenue | $1.1 |
| Operating Profit | $-87.7 |
| Net Income | $-90.3 |
| Net Cash | $-7.7 |
Profit Ratios
| Gross Margin | |
| Operating Margin | -7,940.9 |
| Profit as % of Revenues | |
| Profit as % of Assets | -164.9% |
| Profit as % of Stockholder Equity | -851.2% |
Management Effectiveness
| Return on Equity | -851.2% |
| Return on Assets | -180.1% |
| Turnover Ratio | 0% |
| EBITA |
Balance Sheet and Cash Flow Measures
| Total Assets | $50.1 |
| Total Liabilities | $39.5 |
| Operating Cash Flow | $-77.1 |
| Investing Cash Flow | $-0.7 |
| Financing Cash Flow | $70 |
